Lithium and GSK-3: One inhibitor, two inhibitory actions, multiple outcomes

Richard S. Jope

doi:10.1016/S0165-6147(03)00206-2

Lithium and GSK-3: One inhibitor, two inhibitory actions, multiple outcomes

Richard S. Jope

Research output: Contribution to journal › Short survey › peer-review

393 Scopus citations

Abstract

The intrigue of lithium, the simplest drug in the modern pharmacopoeia, extends from its complex actions in cells to its therapeutic effects as a mood stabilizer. New surprises from studies of glycogen synthase kinase 3 (GSK-3) show that lithium reduces GSK-3 activity in two ways, both directly and by increasing the inhibitory phosphorylation of GSK-3. These dual effects can act in concert to magnify the influence of lithium on crucial GSK-3-regulated functions (gene expression, cell structure and survival).

Original language	English (US)
Pages (from-to)	441-443
Number of pages	3
Journal	Trends in Pharmacological Sciences
Volume	24
Issue number	9
DOIs	https://doi.org/10.1016/S0165-6147(03)00206-2
State	Published - Sep 1 2003
Externally published	Yes

ASJC Scopus subject areas

Toxicology
Pharmacology

Access to Document

10.1016/S0165-6147(03)00206-2

Cite this

@article{1c010e77f8974712b60ee892ade97f1f,

title = "Lithium and GSK-3: One inhibitor, two inhibitory actions, multiple outcomes",

abstract = "The intrigue of lithium, the simplest drug in the modern pharmacopoeia, extends from its complex actions in cells to its therapeutic effects as a mood stabilizer. New surprises from studies of glycogen synthase kinase 3 (GSK-3) show that lithium reduces GSK-3 activity in two ways, both directly and by increasing the inhibitory phosphorylation of GSK-3. These dual effects can act in concert to magnify the influence of lithium on crucial GSK-3-regulated functions (gene expression, cell structure and survival).",

author = "Jope, {Richard S.}",

note = "Funding Information: Research in my laboratory was supported by grants from the NIH. I gratefully acknowledge the research and discussions contributed by members of my laboratory, and apologize to the many authors of important reports that could not be cited because of space limitations.",

year = "2003",

month = sep,

day = "1",

doi = "10.1016/S0165-6147(03)00206-2",

language = "English (US)",

volume = "24",

pages = "441--443",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

publisher = "Elsevier Limited",

number = "9",

}

TY - JOUR

T1 - Lithium and GSK-3

T2 - One inhibitor, two inhibitory actions, multiple outcomes

AU - Jope, Richard S.

N1 - Funding Information: Research in my laboratory was supported by grants from the NIH. I gratefully acknowledge the research and discussions contributed by members of my laboratory, and apologize to the many authors of important reports that could not be cited because of space limitations.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - The intrigue of lithium, the simplest drug in the modern pharmacopoeia, extends from its complex actions in cells to its therapeutic effects as a mood stabilizer. New surprises from studies of glycogen synthase kinase 3 (GSK-3) show that lithium reduces GSK-3 activity in two ways, both directly and by increasing the inhibitory phosphorylation of GSK-3. These dual effects can act in concert to magnify the influence of lithium on crucial GSK-3-regulated functions (gene expression, cell structure and survival).

AB - The intrigue of lithium, the simplest drug in the modern pharmacopoeia, extends from its complex actions in cells to its therapeutic effects as a mood stabilizer. New surprises from studies of glycogen synthase kinase 3 (GSK-3) show that lithium reduces GSK-3 activity in two ways, both directly and by increasing the inhibitory phosphorylation of GSK-3. These dual effects can act in concert to magnify the influence of lithium on crucial GSK-3-regulated functions (gene expression, cell structure and survival).

UR - http://www.scopus.com/inward/record.url?scp=0042379932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042379932&partnerID=8YFLogxK

U2 - 10.1016/S0165-6147(03)00206-2

DO - 10.1016/S0165-6147(03)00206-2

M3 - Short survey

C2 - 12967765

AN - SCOPUS:0042379932

VL - 24

SP - 441

EP - 443

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 9

ER -

Lithium and GSK-3: One inhibitor, two inhibitory actions, multiple outcomes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this